NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer
October 02 2019 - 7:30AM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical
company committed to discovering and developing novel,
first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced the promotion of
Timothy Mayer, Ph.D. from Senior Vice President, Corporate
Development to Chief Operating Officer.
“I am delighted to make this announcement. Tim
joined NextCure at our inception and has contributed significantly
to major NextCure achievements, including our alliance with Eli
Lilly & Company and our recently completed initial public
offering. He has played a pivotal role on the executive management
team leading corporate development, strategy, and business
operations and we are confident he will continue to be instrumental
in the company’s success,” said Michael Richman, NextCure’s
President and Chief Executive Officer. “I look forward to
continuing to work with Tim at this important and exciting time in
our company’s history.”
Dr. Mayer has extensive experience in the
biopharmaceutical industry, including with antibody therapeutics,
small molecule pharmaceuticals and molecular biology research
tools. Prior to joining NextCure, he served in several positions at
MacroGenics, a biopharmaceutical company focused on the treatment
of cancer, where he oversaw all intellectual property matters,
assisted with business development for various licensing
transactions and helped facilitate MacroGenics’ initial public
offering. Before MacroGenics, Dr. Mayer served in several positions
at Banner & Witcoff, an intellectual property law firm, where
he drafted and prosecuted biotech and pharmaceutical applications
and conducted patentability and freedom-to-operate searches in all
areas of biotechnology and small molecule chemistry. Dr. Mayer also
worked on developing cloning systems while at Life Technologies and
Invitrogen. He received his Ph.D. in Microbiology and Immunology
from Penn State University College of Medicine and B.S. degrees in
Microbiology and Biochemistry from California Polytechnic State
University.
About NextCure, Inc. NextCure is a
clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases. Through our proprietary
FIND-IO™ platform, we study various immune cells to discover and
understand targets and structural components of immune cells and
their functional impact in order to develop immunomedicines. Our
initial focus is to bring hope and new treatments to patients who
do not respond to current cancer therapies, patients whose cancer
progresses despite treatment and patients with cancer types not
adequately addressed by available therapies. www.nextcure.com
Cautionary Statement Regarding
Forward-Looking Statements
Statements made in this press release that are not
historical facts are forward-looking statements. Words such as
“expects,” “believes,” “intends,” “hope,” “forward,” “continue” and
similar expressions are intended to identify forward-looking
statements. Examples of forward-looking statements in this press
release include, among others, statements about Dr. Mayer’s future
with NextCure and NextCure’s plans, objectives and intentions with
respect to the identification of immunomedicine targets and the
discovery and development of immunomedicines. Forward-looking
statements involve substantial risks and uncertainties that could
cause actual results to differ materially from those projected in
any forward-looking statement. Such risks and uncertainties
include, among others: our limited operating history and no
products approved for commercial sale; our history of significant
losses; our need to obtain additional financing; risks related to
clinical development, marketing approval and commercialization; and
the unproven approach to the discovery and development of product
candidates based on our FIND-IO platform. More detailed information
on these and additional factors that could affect NextCure’s actual
results are described in NextCure’s filings with the Securities and
Exchange Commission (the “SEC”), including in the Risk Factors
section and throughout NextCure’s Form 10-Q filed with the SEC on
August 12, 2019. You should not place undue reliance on any
forward-looking statements. NextCure assumes no obligation to
update any forward-looking statements, even if expectations
change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Media Inquiries
Shai Biran, Ph.D.
MacDougall
(781) 235-3060
NextCure@macbiocom.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Sep 2023 to Sep 2024